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Abstract
Background: Bladder desensitization has been investigated as an alternative treatment for refractory detrusor
overactivity. Most open and controlled clinical trials conducted with intravesical RTX showed that desensitization
delays the appearance of involuntary detrusor contractions during bladder filling and decreases the number of
episodes of urgency incontinence.
Urgency is being recognised as the fundamental symptom of overactive bladder (OAB), a symptomatic complex
which recent epidemiological studies have shown to affect more than 10% of the Western population. As anti-
muscarinic drugs, the first line treatment for OAB, are far from being able to fully control urgency, the
opportunity to test other therapeutic approaches is created. The present work was, therefore, designed as an
exploratory investigation to evaluate the effect of bladder desensitization on urinary urgency.
Methods: Twenty-three OAB patients with refractory urgency entered, after given informed consent, a 30 days
run-in period in which medications influencing the bladder function were interrupted. At the end of this period
patients filled a seven-day voiding chart where they scored, using a 0–4 scale, the bladder sensations felt before
each voiding. Then, patients were instilled with 100 ml of 10% ethanol in saline (vehicle solution) and 30 days later
a second seven-day voiding chart was collected. Finally, patients were instilled with 100 ml of 50 nM RTX in 10%
ethanol in saline. At 1 and 3 months additional voiding charts were collected.
At the end of the vehicle and 3 months period patients were asked to give their subjective impression about the
outcome of the treatment and about the willingness to repeat the previous instillation.
Results: At the end of the run-in period the mean number of episodes of urgency per week was 71 ± 12 (mean
± SEM). After vehicle instillation, the mean number of episodes of urgency was 56 ± 11, but only 4 patients (17%)
considered that their urinary condition had improved enough to repeat the treatment. At 1 and 3 months after
RTX the number of episodes of urgency decreased to 39 ± 9 (p = 0.002) and 37 ± 6 (p = 0.02), respectively (p
indicates statistical differences against vehicle). The percentage of patients with subjective improvement after RTX
and willing to repeat the instillation at a later occasion was 69%.
Conclusion: In OAB patients with refractory urgency bladder desensitization should be further investigated as
an alternative to the standard management. Additionally, the specific effect of RTX on TRPV1 receptors suggests
that urothelium and sub-urothelial C-fibers play an important role to the generation of urgency sensation.
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Background
Resiniferatoxin (RTX), the ultrapotent capsaicin analogue,
was shown to desensitize TRPV1, a non-specific calcium
channel, which is abundantly expressed in neuronal and
non-neuronal bladder structures, including type C-sen-
sory fibers [1], urothelial cells [2,3] and possibly intersti-
tial cells [4]. Following desensitization, TRPV1 becomes
less responsive to further activation by RTX or similar
compounds and its expression is strongly reduced, both in
the urothelium [3] and in sensory nerve fibers [5]. In addi-
tion, experimental studies have shown that desensitiza-
tion reduces bladder response to distension, as shown by
the increase of the volume threshold to reflex voiding [6]
and decreased activation of sensory driven spinal cord
genes as c-fos [7].
Urgency is being recognised as the fundamental symptom
of overactive bladder (OAB), a symptomatic complex
which recent epidemiological studies have shown to affect
more than 10% of the Western population [8]. Unfortu-
nately, anti-muscarinic drugs, the first line treatment for
OAB, although providing some improvement, are far
from being able to fully control this bothersome lower
urinary tract symptom [9]. This creates the opportunity to
test other therapies that, if promising, can be offered as
second line options.
Bladder desensitization has been exploited in the last dec-
ade as an alternative treatment for refractory detrusor
overactivity [10,11]. Most open [12-15] and controlled
[16-18] clinical trials conducted so far showed that the
number of episodes of urgency incontinence in patients
with detrusor overactivity was decreased by intravesical
RTX at the same time at which the compound delayed the
appearance of involuntary detrusor contractions during
bladder filling and increased bladder capacity. Further-
more, in a controlled study, the global urinary condition
improved in 62% of detrusor overactivity (DO) patients
treated with intravesical RTX but only in 21% of those that
received the vehicle solution alone [18]. The effect of RTX
on urgency was also reported in OAB patients without
DO. In a small open label study RTX showed a trend to
decrease the number of episodes of urinary urgency [19].
The present work was designed to further explore the
effect of bladder desensitization on urinary urgency. As a
primary objective it was investigated if intravesical RTX
could reduce the number of episodes of urinary urgency.
As a secondary objective the effect of bladder desensitiza-
tion on urgency incontinence and urinary frequency was
also analysed. This study was presented in part in abstract
form [20].
Methods
Twenty-three patients (7 males and 16 females with a
mean age of 50 years, range 21–77) with OAB refractory
to antimuscarinics were enrolled during 2005. All patients
had at least 7 urgency episodes per week. Six patients had
a neurogenic cause for OAB symptoms whereas the
remaining patients were idiopathic. All gave written
informed consent approved by the Ethics Committee of
our Institution to receive intravesical RTX. The following
exclusion criteria to enter the study were observed: age less
than 18 years, pregnancy, known cardiovascular, renal,
hepatic or psychiatric disorders, malignant diseases, dura-
tion of the OAB syndrome less than 12 months and con-
comitant bladder diseases, namely lower urinary tract
symptoms suggestive of bladder outlet obstruction and/or
treatments influencing bladder performance. In addition,
patients were excluded in the presence of abnormal hae-
matological and biochemical blood tests, abnormal kid-
ney and bladder ultrasound and a positive urine culture.
The design of the study was the following. At the first visit
the patients were enrolled in the study and entered a run-
in period of 30 days during which anti-muscarinic drugs
or other drugs that could affect bladder function were
stopped. Patients filled a voiding chart of the last 7 days of
this period. At the second visit the voiding chart was col-
lected and patients were instilled during 30 minutes with
100 ml of the vehicle used to prepare the RTX solution,
10% ethanol in saline. The patients were then sent home
for another 30 days. In the last seven days of this period
patients filled another voiding chart. At the third visit the
voiding chart corresponding to the vehicle period was col-
lected and 100 ml of a 50 nM RTX solution were slowly
instilled into the bladder by gravity and left in contact
with the mucosa during 30 minutes. If detrusor contrac-
tions occurred, the solution could freely reflux into the
container and then return into the bladder once the con-
tractions wanned. The patients were sent home at the end
of the treatment. Two additional visits were scheduled at
1 and 3 months after RTX instillation. At the end of each
period, 7 day voiding charts were collected. At the end of
the vehicle and 3 months period patients were asked to
give their subjective impression about the outcome of the
treatment and about the willingness to repeat the previous
instillation. During the duration of the study no urody-
namic studies were performed as the definitions of
urgency and OAB are purely clinic.
A validated scale to assess urinary urgency is not yet avail-
able in the Portuguese language. In addition, the distinc-
tion between the words urge and urgency, possible in the
English language, has no equivalent in Portuguese. There-
fore, the suggestion for describing urgency according to
the circumstances during which it was experienced and by
the impact it had on concomitant activity being carried byBMC Urology 2007, 7:9 http://www.biomedcentral.com/1471-2490/7/9
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the patients was followed to build up a scale easily under-
standable by the patients [21]. The options are listed
below and the system score was taught to the patients at
the first visit. Only options 3 and 4 were considered as
equivalents of urgency. Option 2 was used to refer urge.
0 – "I voided because it was convenient although I did not
feel a bladder sensation".
1 – "I voided because I had the sensation that my bladder
was becoming full and the opportunity to void was con-
venient".
2 – "I voided because I had the sensation that my bladder
was extremely full. I looked for a convenient place to void
without feeling any eminent risk of urine leakage".
3 – "I voided because I had a sudden strong desire to void
which I felt that could cause an urine leakage. I immedi-
ately interrupted what I was doing and looked for a con-
venient place where I started voiding in time".
4 – "I had a sudden strong desire to void that I felt that
could cause urine leakage. Although I immediately looked
for a convenient place to void, I had a leak before starting
voiding".
RTX was obtained from Sigma and a 10 mM stock solu-
tion in pure ethanol was prepared and kept in the dark at
4°C in a glass container. For each instillation 100 ml of a
50 nM solution using 10% ethanol in saline as vehicle was
prepared by one of the authors by adding 0.5 ml of the
stock solution to 90 ml of saline and 9.5 ml of pure etha-
nol. Instillation was carried out within 30–60 minutes
after preparation to minimise RTX absorption by plastic
devices. Instillations of the vehicle solution and of the
RTX solution were carried on without any form of analge-
sia or bladder anesthesia. Oral ciprofloxacin was adminis-
tered for urinary infection prophylaxis at each instillation.
Urgency events, which corresponded to micturitions
scored as 3 or 4, were counted for each patient at the end
of the run-in period, vehicle period and at 1 and 3 months
after RTX instillation. The number of patients in whom
the number of urgency episodes decreased 25% or more
after vehicle instillation and RTX was counted. Patients
who considered to have had a subjective improvement at
the same time points and would repeat instillations if nec-
essary at a later occasion were also counted. The number
of micturitions per week was obtained from the micturi-
tion charts. Data are presented as mean values per week ±
standard error of the mean (SEM). Those at the vehicle
period and at 1 and 3 months after RTX instillation were
compared by a two-tailed paired t-test for means. Percent-
age of patients with ≥25% improvement in urgency epi-
sodes and with subjective improvement after vehicle and
RTX treatment was compared by a z-test. A p < 0.05 was
considered statistically significant.
Results
At the end of the run-in period the mean number of epi-
sodes of urgency per week, that is micturition events pre-
ceded by sensations scored as 3 or 4, was 71 ± 12. The
average number of episodes of urgency after vehicle instil-
lation was 56 ± 11. Nine patients (39%) had a decrease in
the number of episodes of urgency equal or superior to
25%. However, only 4 patients (17%) considered that
their urinary condition had improved enough to repeat
the treatment. The average number of urgency episodes at
1 and 3 months after RTX instillation was 39 ± 9 (p =
0.002 against vehicle) and 37 ± 6 (p = 0.02 against vehi-
cle), respectively (Fig. 1). After RTX a 25% or more
decrease over the number of episodes of urgency counted
at the end of the vehicle period occurred in 14 patients
representing an increase in the percentage of RTX
responders to 60%. However this variation should be
taken as a trend since it did not achieve statistical signifi-
cance (p = 0.2). The percentage of patients with subjective
improvement after RTX and willing to repeat the instilla-
tion at a later occasion increased to 69%. (p = 0.001, Fig.
2).
The episodes of urgency associated with incontinence
were evaluated separately. At baseline the mean number
was 21 ± 5. They decreased to 12 ± 4 after placebo instil-
lation. At 1 and 3 months after RTX the episodes of
urgency incontinence further decreased to 8 ± 3 and 9 ± 3,
respectively. However, these values were not statistically
different from those after vehicle instillation (p = 0.05 and
p = 0.1, respectively).
Number of episodes of urgency at the run-in period, after  the instillation of the vehicle solution and at 1 and 3 months  after 50 nM RTX instillation Figure 1
Number of episodes of urgency at the run-in period, after 
the instillation of the vehicle solution and at 1 and 3 months 
after 50 nM RTX instillation.
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The number of micturitions per week, which was 95 ± 11
at the run-in period, decreased to 87 ± 10 after the vehicle
instillation. A further decrease to 75 ± 8 at 1 month (p =
0.02 against vehicle) and to 75 ± 7 at 3 months (p = 0.03
against vehicle) was observed after the RTX instillation
(Fig 3).
RTX instillation was associated with a slight discomfort,
described by patients as an itch sensation or urgency to
urinate. In no case was analgesic medication required or
instillation interrupted. After RTX treatment none of the
patients reported difficulties in emptying the bladder.
Discussion
The most important finding of the present study was the
decrease of the number of episodes of urinary urgency
induced by bladder desensitization. Urinary frequency
also decreased and urgency incontinence showed a strong
trend to a reduction. These objective changes were accom-
panied by a subjective improvement in more than two
thirds of the patients. In addition, this study further con-
firmed the reports of good tolerability of RTX instillation
in low concentrations [13,16]. In spite of the fact that no
bladder anaesthesia was performed, all our patients car-
ried out the 30 minutes RTX instillation to the end with-
out difficulty.
This study was exploratory and was not designed as a ran-
domized double arm placebo controlled trial due to the
limitations in recruiting patients for an off-license treat-
ment in one single center. Nevertheless mean episodes of
urgency and micturition occurring 1 and 3 months after
RTX instillation were significantly less than those after the
simple instillation of the vehicle solution. In addition,
RTX brought a 25% improvement in the number of epi-
sodes of urgency over the vehicle period to 60% of the
patients whereas vehicle application alone had caused a
similar improvement rate over the run-in period in only
39% of the patients.
Due to the lack of validated scales to quantify urgency in
the Portuguese language we had to build-up a scale to
assess this symptom. As the words urge and urgency have
no equivalent in the Portuguese language we preferred a
scale which evaluated the circumstances in which urgency
occurred and its impact on the patients' daily activities,
rather than its intensity. Although our option might be
object of criticism, actually, the best mean to evaluate and
measure urgency is not yet established and is under
intense controversy. Researchers exist who prefer scales in
which different degrees of urgency intensity are contem-
plated [22,23]. However others only recognise the neces-
sity of distinguishing urgency form urge and consider that
urgency, being a sudden and compelling desire to urinate,
does not have degree of severity [24].
The reason for the improvement associated with RTX
should be explained by its specific affinity to TRPV1
[25,26]. This receptor was recently found to be over
expressed in the trigone of patients with urgency [27]. In
C-fibers RTX binding to TRPV1 causes a massive inflow of
calcium and other ions into the fiber, generating action
potentials and releasing neuropeptides from peripheral
nerve endings [25,26], both events contributing to itch or
urgency sensations reported by some patients in the
present and in previous studies in which RTX instillation
was carried out [14,16]. A transient reduction of bladder
sensory input conveyed to the central nervous system in C
Number of micturition episodes per week at the run-in  period, after the instillation of the vehicle solution and at 1  and 3 months after 50 nM RTX instillation Figure 3
Number of micturition episodes per week at the run-in 
period, after the instillation of the vehicle solution and at 1 
and 3 months after 50 nM RTX instillation.
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Percentage of patients with a 25% or more decrease on the 
number of episodes of urgency per week and percentage of 
patients with subjective improvement and willing to repeat 
the instillation if necessary, after vehicle (red bars) or 50 nM 
RTX instillation (blue bars).
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fibers then follows [7]. The interruption of C-fiber influx
may thus have contributed to the symptomatic improve-
ment observed after RTX instillation in our patients.
It is probable that part of sensory input conveyed in C fib-
ers is not initiated by a direct stimulation of peripheral
nerve endings but results from their activation by neuro-
transmitters and neurotrophic factors released from the
urothelium [28]. RTX binding to TRPV1 present in urothe-
lial cells may, therefore, have contributed to urgency
improvement by disrupting the cross-talk between
urothelial cells and suburothelial C-fibers. Inflow currents
occur in human urothelial cells after TRPV1 activation
suggesting that the receptor in the urothelium retains
properties similar to those described in sensory neurons
[29]. Likewise RTX application is followed by a reduction
in urothelial TRPV1 expression [3]. Thus, RTX treatment
might have reduced the potential of urothelial cells to
release compounds which are known to excite sub-
urothelial sensory fibres [2]. One of these compounds
might be nerve growth factor (NGF) [30]. Although it is
unclear at the moment if TRPV1 excitation enhances NGF
release from urothelium, this neurotrophin was shown to
induce bladder overactivity in experimental animals [31]
and was found in high amounts in the urine of OAB
patients [32].
It is also possible that RTX has prevented the ATP released
from urothelial cells [2] and consequently the activation
of sub-urothelial C-fibers expressing P2X3 receptors [15].
It is known that TRPV1 is involved in ATP release from the
urothelium in response to stretch stimuli [33]. In addi-
tion, animal studies demonstrated that P2X3 receptors are
essential for the generation of bladder contractions and
noxious sensations [34]. As a matter of fact, knocking-out
P2X3 in mice renders the bladder hypoactive and the ani-
mals less reactive to pain [34]. Intravesical RTX decreases
both TRPV1 in urothelial cells [3] and the number of sub-
urothelial P2X3 expressing fibers in the human bladder
[15].
In our study the instillation of 10% ethanol in saline
alone caused a marked improvement in the number of
urgency episodes when compared to the run-in phase. It
seems, however, improbable that such effect was due to a
desensitizing action of ethanol on TRPV1 receptors. In
fact, although ethanol was found to bind TRPV1, it does
not cause its desensitization [35]. In addition, in a recent
clinical trial with patients with neurogenic detrusor over-
activity 10% ethanol in saline alone did not cause any var-
iation on urodynamic parameters in contrast with the
solution containing RTX 50 nM that significantly
increased the bladder volume to first involuntary detrusor
contraction and maximal cystometric capacity [16]. Simi-
lar findings were reported by Kuo et al. In 54 patiens with
refractory DO, 21% of the patients treated with 10% eth-
anol improved at 3 months, a number considerably
smaller that the 62% that improved after RTX 10 nM, four
weekly instillations [18]. Thus, the improvement induced
by 10% ethanol instillation in the present study should be
taken as part of a placebo effect, a commonly recognized
phenomenon in clinical trials involving OAB patients
[36].
Conclusion
This exploratory study indicates that desensitization may
be useful to treat patients with urinary urgency, particu-
larly if refractory to the standard management. This find-
ing also has important pathophysiological implications as
it indicates that C-fiber input plays an important role to
the generation of the urgency sensation. Since at present
RTX is the only compound with desensitizing effect suita-
ble for human use, a randomised placebo controlled
study is justified to further investigate the role of desensi-
tization in the treatment of urgency. The dose for intra-
vesical RTX used in the present work should be considered
as indicative in future studies. In fact, all studies in which
RTX was used to treat OAB symptoms [14,18,19], includ-
ing the present one, used RTX concentrations of 50 nM or
lower. In addition, urodynamics studies should be
included in future studies. Although it was not the case of
this study, urodynamics might elucidate if urgency in
patients with or without detrusor overactivity have the
same origin.
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